We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid Detection of Legionella Offered for Commercial Water Systems

By LabMedica International staff writers
Posted on 02 Apr 2018
A rapid (approximately one hour) DNA microarray-based assay is set to replace classical culture methods for identification of Legionella bacteria in commercial water systems.

The genus Legionella is a pathogenic group of Gram-negative bacteria that includes the species L. More...
pneumophila, the causative agent of legionellosis (all illnesses caused by Legionella) including a pneumonia-type illness called Legionnaires' disease.

Molecular biological detection methods capable of rapidly identifying viable Legionella are important for the control of engineered water systems. The current gold standard based on culture methods takes up to 10 days to show positive results. For this reason, investigators at the Technical University of Munich (Germany) developed a flow-based chemiluminescence (CL) DNA microarray that was able to quantify viable and non-viable Legionella spp. as well as L. pneumophila.

The assay method depends on a measuring chip that was developed in the context of the "LegioTyper" project funded by the German Federal Ministry of Education and Research. This chip not only detected the dangerous pathogen L. pneumophila but also identified which of the approximately 20 subtypes was present.

The foil-based measuring chip used the microarray analysis platform MCR marketed by the biotech company GWK GmbH (Munich, Germany). Using 20 different antibodies, this system provided a complete analysis in less than one hour.

"Compared to previous measurements, the new method not only provides a huge speed advantage," said senior author Dr. Michael Seidel, lecturer in analytical chemistry at the Technical University of Munich, "but is also so cheap that we can use the chip in one-time applications."

Related Links:
Technical University of Munich
GWK


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.